You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Invizius’ ‘angry blood’ research recruits 300th patient

Invizius – a company focusing on second generation therapies autoimmune conditions – has announced that the 300th patient has been recruited to its ‘angry blood’ study.